Pharmaceutical composition for preventing or treating nephritis

MYPI2025001455A0Undetermined Publication Date: 2024-04-12DAEWOONG PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001455
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-12
Filing Date
2023-10-12
Publication Date
2024-04-12

AI Technical Summary

Technical Problem

Current treatments for nephritis, which involves inflammation in the kidneys, are often ineffective in preventing or reversing chronic renal failure, and existing therapies such as steroids and immunosuppressants have limitations in managing diverse causes of kidney inflammation.

Method used

A pharmaceutical composition comprising a specific PRS inhibitor, represented by Formula 1, which inhibits cell growth and reduces inflammatory cells and fibrosis factors, thereby improving kidney function and reducing inflammation in nephritis.

Benefits of technology

The PRS inhibitor effectively inhibits CD4+, CD8+, and gdT cell proliferation, suppresses IL-17 cytokine, and reduces fibrosis and inflammatory markers, thereby improving kidney function and preventing or treating nephritis, including tubulo-interstitial and glomerulonephritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001455_DRAWING_001
    Figure PI2025001455_DRAWING_001
  • Figure PI2025001455_DRAWING_002
    Figure PI2025001455_DRAWING_002
  • Figure PI2025001455_DRAWING_003
    Figure PI2025001455_DRAWING_003
Patent Text Reader

Abstract

The present invention provides a pharmaceutical composition advantageously useful for preventing or treating nephritis.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for the prevention or treatment of nephritis

[0001] The present invention provides a pharmaceutical composition for preventing or treating nephritis.

[0002] Inflammation of the kidneys is broadly referred to as nephritis or nephritis, and the causes of inflammation can include bacterial inflammation and immune response. Depending on the location of the inflammation, it is classified into tubulo-interstitial nephritis (TIN), acute / chronic pyelonephritis, and glomerulonephritis. It can also occur as a complication of other diseases, and depending on the cause, it can be classified into diabetic nephropathy, lupus nephritis, etc. This type of nephritis can cause complications of chronic renal failure, and since recovery of kidney function is difficult once chronic renal failure develops, early and appropriate treatment is essential.

[0003]

[0004] Interstitial nephritis is a disease in which inflammatory cells infiltrate the interstitium between renal tubules, resulting in decreased renal function. Causes of interstitial nephritis include drugs, systemic diseases such as lupus erythematosus (SLE), and infections. Severely decreased urine output (oliguria) occurs in 50% of patients with acute interstitial nephritis, and macroscopic hematuria occurs in 5%. Joint pain, fever, eosinophilia in the blood, and skin rash may also occur, but symptoms may not appear. If the above symptoms of interstitial nephritis appear and BUN and creatinine levels increase due to decreased renal function in blood tests, interstitial nephritis is diagnosed, and steroids are used for treatment.

[0005]

[0006] Glomeruli are tissues composed of clusters of capillaries, the basic units that filter blood in the kidneys. Glomerulonephritis is a disease in which symptoms and signs occur when an inflammatory response occurs in the glomeruli due to immune dysfunction. The causes of glomerulonephritis are diverse, but immunological mechanisms are the primary cause. Glomerulonephritis is diagnosed through urine tests, blood tests, and kidney tissue biopsies, and immunosuppressants are primarily used as treatment.

[0007]

[0008] Meanwhile, prolyl-tRNA synthetase (PRS) is a member of the aminoacyl-tRNA synthetase (ARS) family of enzymes that activates amino acids for protein synthesis. Specifically, ARS forms aminoacyl adenylate (AA-AMP) and then transfers the activated amino acid to the 3-terminal of the corresponding tRNA (translational function). Because ARS plays a key role in protein synthesis, ARS inhibition inhibits the growth and development of all cells. Accordingly, ARS is recognized as a promising target for antibiotics and therapeutic agents that require inhibition of cell overexpression (Nature, 2013, 494: 121-125).

[0009]

[0010] PRS exists and functions as a multisynthetase complex (MSC) in the form of EPRS (Glutamyl-Prolyl-tRNA Synthetase). In particular, among various MSCs, EPRS functions as a translational silencer that suppresses the production of vascular endothelial growth factor A (VEGF A), a key factor in angiogenesis, and has also been reported to be closely related to various solid cancers (Nat. Rev. Cancer, 2011, 11, 708-718).

[0011]

[0012] Accordingly, the inventors of the present invention have conducted extensive research on a method for preventing or treating nephritis and have confirmed that a specific PRS inhibitor, which will be described later, can be used for preventing or treating nephritis, thereby completing the present invention.

[0013] The present invention provides a pharmaceutical composition that can be usefully used for the prevention or treatment of nephritis.

[0014] To solve the above problem, the present invention provides a pharmaceutical composition for preventing or treating nephritis, comprising a compound represented by the following chemical formula 1, or a pharmaceutically acceptable salt thereof:

[0015] [Chemical Formula 1]

[0016] .

[0017]

[0018] The compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof is a compound described in Korean Patent Registration No. 10-2084772, specifically, a substance described as Example 40 of the specification. It is known that the substance can be used as a PRS inhibitor for the prevention or treatment of fibrosis.

[0019]

[0020] The present invention has confirmed that the above substance can also be applied to the prevention or treatment of nephritis, and as can be confirmed in the examples and experimental examples described below, it can be usefully used to prevent or treat nephritis.

[0021]

[0022] Meanwhile, the compound represented by the above chemical formula 1 can be used in the form of a pharmaceutically acceptable salt, and as a salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. Inorganic acids and organic acids can be used. Inorganic acids that can be used include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc., and organic acids that can be used include citric acid, acetic acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, succinic acid, 4-toluenesulfonic acid, glutamic acid, or aspartic acid. Preferably, the pharmaceutically acceptable salt of the compound represented by the above chemical formula 1 is a hydrochloride salt.

[0023]

[0024] In addition, the compound represented by the above chemical formula 1 can be prepared in a crystalline or amorphous form, and when prepared in a crystalline form, can be optionally hydrated or solvated. The present invention may include not only stoichiometric hydrates of the compound represented by the above chemical formula 1, but also compounds containing various amounts of water. Solvates of the compound represented by the above chemical formula 1 include both stoichiometric solvates and non-stoichiometric solvates.

[0025]

[0026] Meanwhile, examples of the nephritis include tubulo-interstitial nephritis, glomerulonephritis, acute pyelonephritis, or chronic pyelonephritis.

[0027]

[0028] The term "prevention" in the present invention refers to any action that inhibits or delays the occurrence, spread, and recurrence of the disease by administering the composition of the present invention, and "treatment" refers to any action that improves or beneficially changes the symptoms of the disease by administering the composition of the present invention. Specifically, the pharmaceutical composition according to the present invention has the effect of improving renal function. In addition, the pharmaceutical composition according to the present invention has the effect of reducing CD4+, CD8+, or gdT inflammatory cells in renal tissue.

[0029]

[0030] The pharmaceutical composition of the present invention can be formulated into oral or parenteral dosage forms according to standard pharmaceutical practice. These dosage forms may contain, in addition to the active ingredient, pharmaceutically acceptable additives such as carriers, adjuvants, or diluents.

[0031]

[0032] Suitable carriers include, but are not limited to, saline, polyethylene glycol, ethanol, vegetable oils, and isopropyl myristate, and diluents include, but are not limited to, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and / or glycine. In addition, the compounds of the present invention can be dissolved in oils, propylene glycol, or other solvents commonly used in the preparation of injectable solutions. In addition, the compounds of the present invention can be formulated as ointments or creams for topical action.

[0033]

[0034] The pharmaceutical dosage forms of the compounds of the present invention can be used in the form of their pharmaceutically acceptable salts or solvates, and can be used alone or in combination with other pharmaceutically active compounds, as well as in appropriate combinations. For example, the pharmaceutical composition according to the present invention may additionally comprise another active ingredient used for the prevention or treatment of nephritis. In addition, when the pharmaceutical composition according to the present invention additionally comprises another active ingredient, the weight ratio of the compound represented by the above chemical formula 1, or a pharmaceutically acceptable salt thereof, to the other active ingredient is preferably 1:0.1 to 1:10.

[0035]

[0036] The compounds of the present invention can be formulated as injections by dissolving, suspending, or emulsifying the compounds in water-soluble solvents such as normal saline, 5% dextrose, or in water-insoluble solvents such as synthetic fatty acid glycerides, higher fatty acid esters, or propylene glycol. The formulations of the present invention can include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, and preservatives.

[0037]

[0038] The pharmaceutical composition according to the present invention may be administered via oral or parenteral routes. Depending on the administration method, the composition according to the present invention may contain 0.001 to 99 wt%, preferably 0.01 to 60 wt%, of the compound represented by the above chemical formula 1, or a pharmaceutically acceptable salt thereof.

[0039]

[0040] The pharmaceutical composition of the present invention can be administered to mammals, including rats, mice, livestock, and humans, via various routes. Any route of administration is conceivable, including oral, rectal, intravenous, intramuscular, subcutaneous, intrauterine, or intracerebroventricular injection.

[0041] The pharmaceutical composition according to the present invention described above can be usefully used for the prevention or treatment of nephritis.

[0042] Figure 1 schematically illustrates the process of separating blood from a normal person using a centrifuge in Experimental Example 1 of the present invention.

[0043] Figure 2 shows the results of inhibition of cell proliferation in CD4+ and CD8+ T cells by the compound of the present invention in Experimental Example 1 of the present invention.

[0044] Figure 3 shows the results of IL-17 cytokine inhibition in gdT cells by the compound of the present invention in Experimental Example 2 of the present invention.

[0045] Figure 4 shows the results of measuring blood BUN and Creatinine, which are primary indicators of renal function, according to treatment with the compound of the present invention in a mouse renal failure treatment model by adenine diet in Experimental Example 3 of the present invention.

[0046] Figure 5 shows the results of measuring the degree of fibrosis through immunochemical staining of mouse kidney tissue after treatment with the compound of the present invention in a mouse renal failure treatment model induced by an adenine diet in Experimental Example 3 of the present invention.

[0047] Figure 6 shows the results of inhibition of fibrosis factors after treating a rat kidney cell line with the compound of the present invention in Experimental Example 3 of the present invention.

[0048] Figure 7 shows the results of inhibition of fibrosis factors after treating human primary kidney cells with the compound of the present invention in Experimental Example 4 of the present invention.

[0049] Figure 8 shows the results of measuring blood BUN and Creatinine, which are primary indicators of renal function, according to treatment with the compound of the present invention in a mouse renal failure prevention model by adenine diet in Experimental Example 5 of the present invention.

[0050] Figure 9 shows the results of measuring the degree of collagen accumulation in kidney tissue after treating a mouse renal failure prevention model by adenine diet with the compound of the present invention in Experimental Example 5 of the present invention.

[0051] Figure 10 shows the results of confirming the effect on damaged glomerular tissue after treating the compound of the present invention to the NTN model in Experimental Example 6 of the present invention.

[0052] Figure 11 shows the results of confirming the effect on damaged glomerular tissue after treating the NTN model with the compound of the present invention in Experimental Example 6 of the present invention through immunochemical staining of mouse kidney tissue.

[0053] Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are intended only to illustrate the present invention and the scope of the present invention is not limited to these examples.

[0054]

[0055] Example

[0056] The following compound was prepared using the same method as Example 40 of Korean Patent Registration No. 10-2084772, and was hereinafter named 'PRSi' or 'Example'.

[0057]

[0058] 1H NMR (500 MHz, MeOD): δ 9.67 (s, 1H). 8.02 (d, 1H), 7.82 (d, 1H), 4.62 (m, 2H), 3.60 (m, 1H), 3.28 (m, 1H), 2.99 (m, 2H), 2.25 (m, 2H), 2.08 (m, 2H), 1.99 (m, 1H), 1.78 (m, 2H), 1.54 (m, 1H)

[0059]

[0060] Experimental Example 1: Efficacy of inhibiting CD4+ and CD8+ T cell proliferation

[0061] Through an adenine diet animal model, it was confirmed that CD4+, CD8+, and gdT cells (IL-17) were the main factors in the renal failure model. Through Experimental Examples 1 and 2 of the present invention, the effect of the compound of the present invention on the main factors was confirmed.

[0062]

[0063] After collecting 10 ml of blood from a normal person, ficoll density gradient medium (Cytiva 17144003) and PBS were added as shown in Figure 1, and the immune cell layer (PBMC) was separated using a centrifuge.

[0064]

[0065] PBMCs were transferred to a new tube using a pipette. After adding RBC lysis buffer to the PBMCs and centrifuging, CD8 or CD4 cells were isolated using CD8 microbeads (Miltenyl 130-045-201) or CD4 microbeads (Miltenyl 130-096-533). CFSE (-(and-6)-Carboxyfluorescein Diacetate, Succinimidyl Ester) labeling solution (Invitrogen C1157) was added to the isolated cells. The compounds of the examples were dissolved in DMSO to make a 5 mM stock, and then treated to 1.25 μM, 2.5 μM, 5 μM, and 10 μM, respectively. After 5 days, the degree of cell proliferation was measured by the amount of CFSE staining using flow cytometry, and the results are shown in Fig. 2.

[0066]

[0067] As shown in Fig. 2, it was confirmed that cell proliferation was inhibited when CD4+ and CD8+ T cells were treated with the compound of the example.

[0068]

[0069] Experimental Example 2: Inhibition of IL-17 factor in gdT cells

[0070] After collecting 10 ml of blood from a normal person, Ficoll density gradient medium (Cytiva 17144003) and PBS were added, and the immune cell layer (PBMC) was separated using a centrifuge. PBMC was transferred to a new tube using a pipette. RBC lysis buffer was added to the PBMC, centrifugation was performed, and 10 ng / ml of human IL-2 and IL-15 proteins (cytokines) were added to the cells and cultured (for the purpose of inducing IL-17A). The compound of the example was dissolved in DMSO to make a 5 mM stock, and then 10 μM of the compound of the example was treated. On the 3rd and 5th days of cytokine treatment, 10 ng / ml of human IL-2 and IL-15 proteins (cytokines) were additionally added, centrifugation was performed, and the supernatant was collected. The IL-17A expression level was confirmed using the IL-17A ELISA kit (R&D Systems DY371) with the collected supernatant, and the results are shown in Fig. 3.

[0071]

[0072] As shown in Fig. 3, when the compound of the example was treated on gdT cells isolated from normal blood, it was confirmed that IL-17 cytokine, a major factor of gdT cells, was suppressed.

[0073]

[0074] Experimental Example 3: Improvement of Renal Function and Antifibrotic Effects - Adenine Diet-Induced Renal Failure Treatment Model in a Mouse

[0075] As described in the literature (Ali et al. J Pharmacol Toxicol Methods 2013; Jia et al. BMC Nephrol 2013; Tanaka et al. Am J Pathol 2009), C57BL / 6 male mice were fed a diet containing adenine. Two weeks after the start of adenine intake, 5 mg / kg, 10 mg / kg, and 20 mg / kg of the compound of the example were administered orally daily for two weeks (Fig. 4). The negative control group (vehicle) was administered physiological saline. Blood BUN and creatinine, the primary indicators of renal function, were measured. The results are shown in Fig. 4.

[0076]

[0077] As shown in Fig. 4, it was confirmed that the compound of the example was administered orally (once a day) and that the deterioration of renal function was significantly suppressed in a dose-dependent manner.

[0078]

[0079] Additionally, the degree of fibrosis was measured using immunochemical staining of the mouse kidney tissue, and the results are shown in Figure 5.

[0080]

[0081] As shown in Fig. 5, it was confirmed that oral administration of the compound of the example dose-dependently and significantly inhibited collagen over-accumulation in renal tissue in a mouse renal failure model induced by an adenine diet.

[0082]

[0083] In addition, the mouse kidney tissue was ground using a tissue homogenizer (Qiagen TissueLyser II), centrifuged, and the supernatant was collected. Cells were separated and cultured by centrifugation from the supernatant. The cultured cells were treated with 5 ng / ml TGFb and 2.5 μM, 5 μM, and 10 μM of the example compounds, respectively, and the cells were harvested after 48 hours, and quantitative analysis of fibrosis factor proteins was performed by western blot. The results are shown in Fig. 6.

[0084]

[0085] As shown in Fig. 6, when the rat kidney cell line (NRK-49F cell line) was treated with the example compound, it was confirmed that fibrotic factors (collagen, Fibronectin, αSMA) were significantly inhibited.

[0086]

[0087] Experimental Example 4: Inhibitory Effect of Fibrosis Factors

[0088] Human kidney tissue (preserved after biopsy) was added to digestion buffer, minced with scissors, and then incubated in a shaker for 90 minutes to disintegrate. The disintegrated tissue was filtered through a 70 μm filter cell strainer, and the remaining tissue was filtered once more using a 40 μm filter cell strainer. The filtered disintegrated tissue solution was centrifuged to isolate and culture the cells. The cultured cells were treated with 5 ng / ml TGFb and 1.25 μM, 2.5 μM, and 5 μM of the example compounds, respectively. After 48 hours, the cells were harvested and quantitative analysis of fibrosis factor proteins was performed by western blot. The results are shown in Fig. 7.

[0089]

[0090] As shown in Fig. 7, it was confirmed that the treatment of human primary kidney cells with the example compound significantly inhibited fibrotic factors (collagen, Fibronectin, αSMA).

[0091]

[0092] Experimental Example 5: Improvement of Renal Function and Antifibrotic Effects - Adenine Diet-Induced Renal Failure Prevention Model in a Mouse

[0093] As described in the literature (Ali et al. J Pharmacol Toxicol Methods 2013; Jia et al. BMC Nephrol 2013; Tanaka et al. Am J Pathol 2009), C57BL / 6 male mice were fed a diet containing adenine. Simultaneously with the start of adenine intake, 5 mg / kg, 10 mg / kg, and 20 mg / kg of the example compound were administered orally daily for 4 weeks (Fig. 8). The negative control group (vehicle) was administered physiological saline. Blood BUN and creatinine, the primary indicators of renal function, were measured. The results are shown in Fig. 8 below.

[0094]

[0095] As shown in Fig. 8, when normal mice were fed an adenine diet for 4 weeks and simultaneously orally administered the example compound (once a day) for 4 weeks, it was confirmed that the deterioration of renal function was significantly and dose-dependently suppressed. In other words, the study showed a preventive effect by suppressing renal damage caused by the adenine diet.

[0096]

[0097] In addition, the degree of fibrosis was measured using immunochemical staining of the mouse kidney tissue. The results are shown in Fig. 9. As shown in Fig. 9, it was confirmed that when the compound of the example was administered orally simultaneously in a mouse renal failure model induced by an adenine diet, excessive collagen accumulation in the kidney tissue was significantly and dose-dependently suppressed.

[0098]

[0099] Experimental Example 6: Improvement of renal function and antifibrotic efficacy - NTN (Nephrotoxic serum-induced nephritis) model

[0100] C57BL / 6 male mice were sensitized with 200 μg sheep IgG and Freund's complement adjuvant, and disease was induced 5 days later by injection of 10 μg sheep nephrotoxic serum. From the day of disease induction, the example compounds were orally administered at 5 mg / kg, 10 mg / kg, and 20 mg / kg for 7 days, respectively. The negative control group was administered (vehicle) saline. Renal function (uPCR, BUN) was evaluated on the 8th day. The results are shown in Figure 10.

[0101]

[0102] The NTN model is a glomerulonephritis model that causes inflammation in the glomeruli, leading to proteinuria. As shown in Fig. 10, this inflammation occurred specifically in the glomeruli (left vehicle in Fig. 10), and it was confirmed that damage to the renal tubules occurred little (right vehicle in Fig. 10). In addition, when the example compound was orally administered for one week, proteinuria was significantly reduced, indicating that it was effective on damaged glomerular tissue (PRSi 5 mg / kg, left PRSi in Fig. 10, and Fig. 11).

Claims

1. A pharmaceutical composition for preventing or treating nephritis, comprising a compound represented by the following chemical formula 1, or a pharmaceutically acceptable salt thereof: [Chemical Formula 1] .

2. In paragraph 1, The above nephritis is tubulointerstitial nephritis, glomerulonephritis, acute pyelonephritis, or chronic pyelonephritis. Pharmaceutical composition.

3. In paragraph 1, The pharmaceutically acceptable salt is hydrochloride, Pharmaceutical composition.

4. In paragraph 1, The above pharmaceutical composition has an effect of improving renal function, Pharmaceutical composition.

5. In paragraph 1, The above pharmaceutical composition has an effect of reducing inflammatory cells CD4+, CD8+ or gdT in renal tissue. Pharmaceutical composition.